Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.50
+0.37 (7.21%)
At close: Jun 26, 2026, 4:00 PM EDT
5.55
+0.05 (0.91%)
After-hours: Jun 26, 2026, 7:19 PM EDT
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $251.15K in the quarter ending March 31, 2026, a decrease of -2.61%. This brings the company's revenue in the last twelve months to $7.94M, up 115.44% year-over-year. In the year 2025, Coya Therapeutics had annual revenue of $7.95M with 123.57% growth.
Revenue (ttm)
$7.94M
Revenue Growth
+115.44%
P/S Ratio
16.25
Revenue / Employee
$992,377
Employees
8
Market Cap
129.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.95M | 4.39M | 123.57% |
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 123.87M |
| ADC Therapeutics | 79.18M |
| Spero Therapeutics | 61.19M |
| NRx Pharmaceuticals | 2.29M |
| Connect Biopharma Holdings | 233.00K |
| NeOnc Technologies Holdings | 39.99K |
| Genelux | 8.00K |
| Fractyl Health | 3.00K |
COYA News
- 1 day ago - Coya Therapeutics Transcript: AGM 2026 - Transcripts
- 2 days ago - Coya Therapeutics Transcript: Investor update - Transcripts
- 8 days ago - Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting - Business Wire
- 11 days ago - Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - Business Wire
- 18 days ago - Coya Therapeutics initiates first cohort of patients in ALSTARS trial - TheFly
- 18 days ago - Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase - Business Wire
- 21 days ago - Coya Therapeutics initiated with a Buy at Roth Capital - TheFly
- 25 days ago - Coya Therapeutics Slides: Investor presentation - Filings